Skip to main content
. Author manuscript; available in PMC: 2019 Dec 4.
Published in final edited form as: Cell Metab. 2018 Aug 30;28(6):833–847.e8. doi: 10.1016/j.cmet.2018.08.008

Figure 7. PCr energy shuttle is a metabolic vulnerability in HER2+ breast cancer cells in vivo.

Figure 7.

(A) Tumor growth in nude mice with BT474-R tumors treated with 0.3% Cyclo-Cr in drinking water versus regular drinking water. The Cyclo-Cr and PCr concentrations in the harvested BT474-R tumors determined by HPLC analysis are also shown below. N=8 in each group. (B) Tumor growth of HER2+ PDX #4 in NSG mice treated with 0.3% Cyclo-Cr in drinking water versus regular drinking water. The Cyclo-Cr and PCr concentrations in harvested PDX #4 tumors determined by HPLC analysis are also shown below. N=6 in each group. (C) Left: Tumor growth in NSG mice with trastuzumab-resistant HER2+ PDX #4 under various drug combinations (a total of 6 groups; control, Cyclo-Cr alone, lapatinib alone, Cyclo-Cr plus PCr, Cyclo-Cr plus lapatinib, and Cyclo-Cr plus lapatinib plus PCr). Cyclo-Cr was administered in drinking water at 0.3%, lapatinib was administrated orally at 50 mg/kg/day and PCr was administered at 400 mg/kg/day intraperitoneally. Right: Bar graphs represent tumor volume in mice with various treatments at day 20. N=9 in each group. P values were determined by a two-tailed Student’s t test. *P<0.05, **P<0.01, ***P<0.001.